FINDING ANSWERS

A long standing question for management of diabetic nephropathy and its prevention is finally getting answers as up to 40% of type II diabetics will eventually suffer from kidney failure.

National Kidney Foundation recommends a patient of Type II Diabetes mellitus should go under blood, urine (proteinuria) test and blood pressure check up once a year as up to 40% of type II diabetic patients will eventually suffer from Kidney Failure.

The primary sign include Albumin/Protein in urine, High BP, ankle and leg swelling, leg cramp,more urination in night, less need of insulin and anti-diabetic drug, weakness, itching – they may indicate for an intervention after the KFT. Once such intervention is Neeri KFT , which helps protect from diabetes induced nephron damage by exerting potent aldose reductse inhibitory activity and check diqabetes induced oxidative damage due to presence of Solanum nigrum and Boerhavia diffusa.

Boerhavia diffusa(Punernava) -nephroprotective and nephrocorrective action is well documented and now also scientifically validated as Dr R.H.Singh and Padamshree Professor Dr. K. N. Udupa in their book Advances in Ayurvedic medicine : Diseases of the kidney and urinary tract writes that this ancient and traditional system has conceived the existence of an urinary system with description of the anatomy and possible physiology of kidney (vrikka). Ayurvedic texts vividly describe a wide range of disease entities and pathological states such as Mutraghata, Mutrakricchara, Ashmari, Prameha and many other covering almost all clinical entities known in today's medicine.

They further writes about study on Punernava (Boerhaavia diffusa Linn.) due to its use in the treatment of diseases of urinary system and the possibility of the presence of regenerative property of Punernava as its name suggests and due to the excellent regenerative capacity possessed by the kidneys. Punernava has diuretic, anti-inflammatory and possible antibacterial and cardiotonic effect. By virtue of such properties this drug initiates early recovery of the kidneys from different diseases and facilitates regenerative repair.

This was confirmed later by a study published in The Indo American Journal of Pharmaceutical research which gauged the efficacy of Punernava in a herbal formulation named NEERI KFT which showed good results in experimental subjects as it significantly prevented the altered serum and urinary biochemical parameters and histological renal tubular damaged by lead acetate. A clinical study was also conducted to study the efficacy of Neeri KFT and the report showed the promising results.

TRADITIONALLY IMPORTANT HERB- PUNERNAVA (BOERHAVIA DIFFUSA)

The plant B. diffusa (Family: Nyctaginaceae) is mentioned in the Atharveda with the name “Punernava”, as the aerial part of the plant dries up during the summer season and regenerate again during the rainy season. It is commonly identified as Raktapunarnava, Shothaghni, Kathillaka, Kshudra, Varshabhu, Raktapushpa, Varshaketu, and Shilatika in Ayurveda, the plant is considered to be light (Laghu), dry (Ruksha) and hot potency (Ushna veerya) and is also known to alleviate all three doshas.

Distribution: B. diffusa is widely diffused, occurring throughout India, and southern United States.

Description:  A spreading, prostrate herb, stem reddis. Leaves ovate, obtuse, and undulate along margins. Flowers pink.

Collection: During rainy seasons.

Part use: Whole plant; Root

Medicinal Importance

The whole plant (leaves, stems and roots), specific part have long history of use by indigenous and tribes as medicine to cure kidney diseases and documented in Indian Pharmacopoeia as diuretic. B. diffusa is an important herbal constituent of various ayurvedic formulations. It has been used in various formulations meant for various inflammatory conditions, jaundice, asthma, rheumatism, kidney disorders, ascites, anemia, and gynecological disorders. Diuretics are the first line of therapy in ascites because all of these diseases involve abnormalities in fluid dynamics in the body; however hepatoprotective activity of B. diffusa would be an added benefit in treating various associated diseases. B. diffusa contains various categories of phyto-constituents, for example, flavonoid glycosides, isoflavonoids (rotenoids), phyto-steroids (ecdysteroid), alkaloids, and phenolic and lignin glycosides. The plant is rich in alkaloids which are the main medicinally active component and it can very efficiently decrease the albumin and urea levels in the body. The first pharmacological studies have demonstrated that the roots of B. diffusa exhibits anti-inflammatory properties over kidneys. Punarnava is regarded therapeutically highly efficacious in the form of a powder or an aqueous decoction, for the treatment of renal inflammatory disease and clinical problems such as nephritic syndrome and comparable to corticosteroids. Recent report of B. diffusa also showed improvement in most outcome variables like Hb, potassium, phosphorus by day 30 and urinary protein by day 90, and a greater increase in serum potassium in CRF over experimental subjects. The use of B. diffusa could also be beneficial in congestive heart failure by means of decreasing cardiac load and ACE inhibitor activity. Punarnava is found to enhance the bioavailability of structurally and therapeutically diverse drugs, possibly by modulating membrane dynamics with cytoskeletal function, resulting in an increase in the small intestine absorptive surface, thus assisting efficient permeation through the epithelial barrier so it imparts bioavailability enhancing effect to the Punarnava Swaras.

TREATING CKD PATIENTS WHO ARE NOT ON DIALYSIS: ROLE OF NUTRITIONAL MANAGEMENT THERAPY IN KIDNEY DISEASE

History

Apprehending the power of nutritional therapy in preserving the kidney health and medicament has its rational in ancient knowledge of science. Ancient writing of the Indian Ayurveda, provides information on this subject. Woefully, the current development in lifestyle and industrialized refining systems of food has obscured the old knowledge with the commercial trend in market. Ayurveda puts whacking value on diet and dietary habits known as “pathya”(to be used) means those foods and activities, which does not do any damage to the body and which gives happiness to body and mind. Eat to live a healthy and disease free life is the philosophy of Ayurvedic nutrition.

“Pathya sati gadartasya kimoshadhnishevaney Apathya sati gadartasya kimoshadhnishevaney”. (Ayurved Sarsangrah)

Ayurvedic treatment encompasses trio of Aushadh (medicament) Anna (Do’s and don’ts of diet) and Vihar (lifestyle). It has been stated in Ayurveda that if an individual is suffering from any ailment and if following stringently the “pathya” and “apathya” he may not entail medicine or in simpler words Virtuous diet is the key of the longevity and quality of life. This article serves as a dietary primes for the both non-nephro and nephro physician assistant by outlining the peer-reviewed best practices that are available and encouraged for patient with kidney disease.

Kidney Disease

The disease is defined as a reduction kidney function over time and is characterised by anuria, oligospermia, dysuria and retention of urine. The kidneys regulate the composition and volume of blood, remove metabolic wastes in the urine, and help control the acid/ base balance in the body. They activate vitamin D needed for calcium absorption and produce erythropoietin needed for red-blood-cell synthesis. Kidney also makes an enzyme, rennin which affects blood pressure through negative feedback. Kidney disease is characteristically a progressive disease. Reduction of kidney function—defined as an estimated glomerular filtration rate (eGFR) < 60 mL/min/1.73 m2 and/ or Evidence of kidney damage, including persistent albuminuria. As eGFR declines, complications occur more commonly and are more severe.

These may include:

  • Malnutrition.
  • Metabolic acidosis due to reduced acid (hydrogen ion) excretion.
  • Hyperkalemia.
  • Mineral imbalance and bone disorder (calcium, phosphorus, and vitamin D).
  • Anemia due to impaired erythropoiesis and low iron stores.
  • Cardiovascular disease (CVD).

The nutritional management of kidney disease can affect long term health and quality of life. The goal for nutritional management is optimal metabolic control through balance between food intake, physical activity and if necessary medication to avoid complication. All people with kidney should receive individual advices on nutrition from a registered dietician or from registered Vaidya’s. The nutritionist under the directive of Vaidya can apply the nutrition guideline while considering current and intake, individual energy need, life stage, life style and any medical conditions of the individual with kidney disease.

In kidney disease, the aim of nutrition intervention is prevent, monitor malnutrition, metabolism disorders, hyperkalaemia, CKD mineral and bone mineral disorder, calcium, phosphorous, parathyroid hormone, vitamin D, Anaemia, cardio vascular disease all through coordination of food especially protein, balancing of calcium, supplement iron, dietary restriction to phosphorous, potassium, salt and physical activity.

Management of nutritional goals for kidney disease:
The motive of medical nutrition therapy for the people with kidney disease is to continue good nutritional status, slow progression and to treat complications.  For the people with kidney disease specific advice regarding dietary therapy will vary from patient to patient and need to be based clinical and laboratory finding. The process of dietary counselling often starts with a simple education session highlighting the need to alter diet in the context of CKD. The  function of different nutrients in the body, the danger of excesses or deficiencies of certain nutrients, the food that are allowed, those that should be restricted and the support structure available to practically implement there changes in everyday living. Also, the dietary/ nutritional education is usually targeted at the house hold of the CKD patient rather than the individual patient. Nutrition and all form of kidney management should be individualised. The nutritional management of kidney disease follows the principle Ancient text to healthy eating” or Indian chronic kidney disease guideline or clinical practice guideline nutrition in CKD UK renal association/ national kidney foundation. Nutritional management seeks to improve or maintain the following-

  • The quality of life for people with CKD.
  • The physiological health of individual with CKD by establishing and maintain serum creatinine, urea and albuminuria.
  • The nutritional status of people with CKD, by recognising that their micro and macronutrient requirement are similar to those of the general population.
  • Management of CKD complications (anaemia, bone disease, malnutrition).

Chronic Kidney Disease (CKD) and Diet: Assessment, Management, and Treatment

Assess Kidney Function and Damage

Test and Its Relevance Results Dietary Intervention
Estimated Glomerular Filtration Rate (eGFR)

eGFR estimates kidney function. As eGFR declines, complications are more likely and more severe.

 

eGFR (mL/min/1.73m2)

Not diagnostic of CKD ≥ 60

CKD 15–59
Kidney failure < 15

Evaluate eGFR to assess kidney function; track over time to monitor effectiveness of diet therapy.

Stable eGFR may indicate therapy is working.

Decline of eGFR reflects progression of CKD.

Additional Information:
Natural Sources:
Saccharum officinalis (decoction of root)*
Boerrhavia diffusa  (fresh juice)*
Solanum nigrum (fresh juice)*
Benincasa hispida (seed powder)
Carica papaya (unripe)fruit

Rheum emodi

Coriandum sativum

Urine Albumin-to Creatinine Ratio (UACR)
UACR is the preferred measure for screening, assessing, and monitoring kidney damage. UACR estimates 24-hour urine albumin excretion. Unlike a dipstick test for urine albumin, UACR is unaffected by variation in urine concentration.
UACR (mg/g)

Normal 0–30

Albuminuria > 30

Evaluate UACR over time to assess response to therapy and monitor progression of CKD.

Elevated albuminuria may reflect higher risk for progression.

A decrease in urine albumin may reflect response to therapy and may be associated with improved renal and cardiovascular outcomes.

Additional Information:
Natural Sources:
Boerrhavia diffusa  (fresh juice)*
Moringa oleifera (fresh juice of leaves)

Slow Progression Therapy

Therapeutic Goal and Its Relevance Ranges/Goals Dietary Intervention
 

Control Blood Pressure
Blood pressure control slows progression of CKD and lowers CVD risk.
Sodium plays a large role in blood pressure control in CKD as a result of alterations in sodium excretion by the kidneys.

Less than 140/90 mmHg. ·  Limit sodium intake to 2,300 mg a day or less (IOM, 2013).

Weight reduction may be beneficial.

Monitor serum potassium in patients on renin angiotensin aldosterone system (RAAS) antagonists; limit dietary potassium intake when serum potassium > 5 mEq/L.

Additional Information:
Natural Sources:
Terminalia arjun (decoction of bark)*
Emblica officinalis (fresh juice)
Euryale ferox (fruit)
Coriandum sativum(seed)*
Nelumbo nucifera (flower,rhizome)
 

Reduce Albuminuria

Decreased albuminuria is associated with slower progression of CKD, particularly in diabetics. Limiting dietary protein may reduce albuminuria and improve blood glucose control, hyperlipidemia, blood pressure, renal bone disease, and metabolic acidosis. (deZeeuw et al, 2004).

Reduce or stabilize the amount of albumin lost in the urine. Limit excessive dietary protein as follows:
Non diabetic: 0.8 g protein/kg/day.Diabetic: 0.8-1.0 g protein/kg/day.
Evidence suggests that further lowering to 0.6 g protein/kg/day in non-diabetic patients may be beneficial, but adherence is difficult. Some patients may be able to achieve this level with intensive counselling.

Additional Information:
Natural Sources:
Vetiveria zizanioides (root powder)*

Coriandrum sativum (whole plant powder)*

Hemidesmus indicus (root powder)*
Moringa oleifera (fresh juice of leaves)
 

Manage Diabetes

Blood glucose control may help slow progression of CKD (DCCT,1993; UKPDS,1998)

Good control of newly diagnosed diabetes may slow progression of CKD. Tight control in diabetes of long duration may not be indicated.

Individualize A1C/eAG goal
eAG = estimated average glucose
Consider less-stringent control for patients with histories of hypoglycemia, the elderly, and patients with multiple co-morbid conditions.
Instruct patients to treat hypoglycemia with cranberry juice cocktail, grape or apple juice, glucose tablets, or 10 jelly beans to prevent hyperkalemia.

Prevent, Monitor, and Treat Complications

Complication and Its Relevance Ranges/Goals Dietary Intervention
 

Malnutrition

Malnutrition is common in CKD; as eGFR declines, so may appetite. Malnutrition in CKD patients is associated with increased morbidity and mortality.

Albumin > 4.0 g/dL
Normal range: 3.4–5.0 g/dL
Serum albumin < 4.0 g/dL, prior to initiation of dialysis, may predict morbidity and mortality
(Kaysen et al, 2008).
Blood urea nitrogen (BUN) < 20 mg/dL
Manage with adequate calories and nutrients.
A low protein diet (0.6 g/kg) may require supplemental riboflavin and cyanocobalamin. Supplemental pyridoxine may be beneficial due to medication-vitamin interactions.
It may be prudent to provide adequate amounts of thiamin and folic acid. High doses of vitamin C are not recommended. Data do not support routine supplementation with niacin and vitamins A, E, and K. In advanced CKD, certain vitamins may accumulate due to reduced excretion (Steiber & Kopple, 2011).

Additional Information:
Natural Sources:
Chena (made from cow milk)
Euryale ferox (fruit)
 

Metabolic Acidosis

Patients with CKD are at risk for metabolic acidosis as a result of reduced excretion of acid load.

Bicarbonate (CO2) > 22 mEq/L
Normal range: 21–28 mEq/L
Dietary protein is a source of metabolic acid. Serum bicarbonate levels may increase with dietary protein restriction. (Gennari et al, 2006)
Sodium bicarbonate supplementation may be prescribed to improve nutritional parameters and slow rate of CKD progression (de Brito-Ashurst et al, 2009). Monitor blood pressure closely when this medication is used, as some patients may experience elevated blood pressure associated with increased sodium load.

Additional Information:
Natural Sources:
Chena (made from cow milk)
Achyranthes aspera (fresh juice)
Cichorium intybus (rhizome)*
Coriandrum sativum (seed decoction)*
 

 

Hyperkalemia
Patients with CKD are at risk for hyperkalemia as a result of reduced potassium excretion,
intake of high-potassium foods, metabolic acidosis, and medications that inhibit potassium excretion, such as RAAS antagonists for blood pressure control.

Potassium: 3.5–5.0 mEq/L
Hyperkalemia is usually not seen until CKD is advanced, but may be seen at higher eGFRs in people with diabetes.
Counsel patients to restrict dietary potassium when serum level is 5.0 mEq/L or higher.
Caution patients to avoid potassium-containing salt substitutes.
Instruct patients with diabetes to treat hypoglycemia with cranberry juice cocktail, grape or apple juice, glucosetablets, or 10 jelly beans to prevent hyperkalemia.
Counsel patients to adhere to sodium bicarbonate therapy, if prescribed. Correction of acidosis may lower potassium.
 

CKD Mineral and Bone Mineral Disorder (CKD-MBD)
CKD-MBD is renal bone disease that occurs when the kidneys fail to maintain serum calcium and
phosphorus levels.

See sections on calcium, phosphorus, parathyroid hormone (PTH), and vitamin D. Existing guidelines on management of CKD-MBD reflect consensus rather than high-grade evidence. Early intervention may help prevent vascular calcification and secondary hyperparathyroidism.
The kidneys maintain calcium and phosphorus levels and activate vitamin D. As kidney function declines, complex interactions occur that affect calcium, phosphorus, vitamin D, and the parathyroid gland. Abnormal levels of PTH (measured as intact or iPTH) may be seen. Mineral and bone disorders may result from these interactions. See the specific sections that follow.

Additional Information:
Natural Sources:
Chena (made from cow milk)
Banana
Almond
Euryale ferox (fruit)
Trigonella foenum-graecum (seed)
 

Calcium

Control of calcium and phosphorus levels helps to control PTH.

Calcium: 8.5–10.2 mg/dL Dietary calcium recommendations for CKD have yet to be established.

Calcium-based phosphate-binding medications can increase total daily intake and elevate calcium.
Supplementation with active vitamin D increases the risk for hypercalcemia.
Use formula to correct calcium with hypoalbuminemia: Corrected calcium (mg/dL) = serum calcium (mg/dL)+0.8(4.0 -serum albumin g/dL)

Additional Information:
Natural Sources:
Trichosanthes dioica (fruit)*
 

Phosphorus
Control of phosphorus and calcium levels helps control PTH.

Phosphorus: 2.7–4.6 mg/dL
Maintain within normal range.
Serum phosphorus levels may be
“normal” until CKD is advanced
If serum phosphorus is elevated, dietary phosphorus restriction may be indicated. The recommended level of restriction has yet to be determined in CKD.
Dietary protein restriction decreases phosphorus intake. If further restriction is needed, counsel patients to reduce intake of foods with added phosphorus. (Uribarri, 2007).
Counsel patients to read ingredient lists for “phos” to identify foods with phosphate additives, as these additives may be absorbed more efficiently than food sources.
Limiting whole grains may help if further reduction is needed.
Phosphorus binders may be prescribed to lower phosphorus levels. Counsel patients to take binders with meals to help limit absorption of phosphorus from food and beverages.
 
 

Parathyroid Hormone (PTH)
Secondary hyperparathyroidism (elevated PTH) is associated with the most common cause of bone
disease in CKD.

Normal PTH < 65 pg/mL
Measured as iPTH
PTH varies by level of kidney function and type of bone disease
Dietary phosphorus restriction and use of active vitamin D or its analogs may help control PTH levels in CKD. Calcium supplementation may help as well.
 

Vitamin D

The kidneys activate 25(OH) D (calcidiol) to 1, 25 (OH ) 2D (calcitriol or active vitamin D). Reduction of kidney function results in decreased production and conversion of calcidiol to calcitriol. There may be corresponding imbalances of calcium, phosphorus, and PTH.

Vitamin D ≥ 20 ng/Ml.

Measured as 25(OH)D

Maintain within normal range (IOM, 2011).

Supplementation may be indicated. Specific requirements in CKD have yet to be determined.

Ergocalciferol (vitamin D2) or cholecalciferol (vitamin D3) may be used in early CKD to replete vitamin D.
Active vitamin D (calcitriol) or its analogs (doxercalciferol, paricalcitol, or alfacalcidol) may be used as eGFR declines (ibid).
Monitor for hypercalcemia and/or hyperphosphatemia when using supplements. Active vitamin D increases calcium and phosphorus absorption.

Anemia
Anemia may develop early during the course of CKD due to inadequate synthesis of erythropoietin by the kidneys.
Hemoglobin 11–12 g/dL
Without CKD:
Women: 12–16 g/dL
Men: 14-17 g/dL
Transferrin Saturation (TSAT) >20%
Ferritin > 100 ng/mL
Without CKD:
Women: 18–160 ng/mL
Men: 18–270 ng/mL
 

Both iron supplementation and injectable erythropoiesis-stimulating agents (ESAs) have been used to correct anemia. The risks and benefits of these treatments in CKD are not yet defined. (Besarab & Coyne, 2010).

Additional Information:
Natural Sources:
Beans
Roasted moog
Brown rice
Green leafy vegetable
Raisins
Hemidesmus indicus*
 

Cardiovascular Disease (CVD)

Patients with CKD are at high risk for developing CVD; the risk increases as eGFR declines.
Restoring immunity

Oxidative stress, largely contributes to immune system dysregulation

Total cholesterol < 200 mg/dL
LDL cholesterol < 100 mg/Dl
HDL cholesterol > 40 mg/dL
Triglycerides < 150 mg/dL
Decreasing intake of saturated and trans fats (substituting for monounsaturated and polyunsaturated fats), along with physical activity, can help control hyperlipidemia and reduce inflammation.

Administration of the antioxidant N-acetyl-cyteine has been found to significantly reduce the incidence of cardiovascular events.

Additional Information:
Natural Sources:
Boerrhavia diffusa  (fresh juice)*
Nelumbo nucifera (fresh juice rhizome)*
Albizzia lebbeck (fresh juice bark)*

Source: (*Herbs: Mentioned in Ayurvedic System of Medicine; National kidney disease education programme)
Future direction

This information is helpful to identify inconsistencies of case across the globe and to further monitor progress in future patients may be motivated to take a mass responsibility in preventing the progression of CKD through lifestyle interventions and treatment adherence. The raise awareness about kidney disease will bring together the best available evidence to inform strategies to reduce national, regional and global burden of the disease and its risk factors.

AYURVEDA: ‘MOTHER OF MEDICAL SCIENCE HAS ITS OWN SCIENCE’

Ayurveda has been accounted for transmittance of ancient medical knowledge from Gods to successors, even before mankind existed. Aspects of Ayurveda have their roots in the un-scientific era which speaks skills of medical science that are being followed & gained emergence in today’s scientific and medically progressed age. The privilege of first ever medical science to be introduced to humans has been held by Ayurveda. Yet, its acceptance has been hugely denied and put under scrutiny for not being validated on scientific parameters alike demanded in modern medical science. However, none realizes the fact that Ayurveda has its own tradition, vogue, prescript & prowess of remedial so it is unlikely to bring down any distinct system to comparison with it. Although, every medical system is comprehensively trying to serve the same purpose of alleviating the illness from human life still they all are different in their mannerism of treatment.

‘HOLISM’ IS THE CONCEPT THAT AYURVEDA FOSTERS

SAM DOSHA SAMAAGANI SAM DHAATU CH MALAYKRIYA,
PRASAN AAK MINDRIYAA MANAAH SWAASTHAYA DHIYATE


Ayurveda is a science that conceptualizes the healthy living first which includes the wellness of body, mind & soul. Prevention of the disease & cure comes later and is distinguishable from every other system that principally concerns about subsiding the symptoms.

If we track down there will be many diseases which are either not being diagnosed or even if diagnosed they have no cure in any other followed medical system but Ayurveda have had achieved unparalleled success following its approach. One such example can be taken of the disease ‘LUCODERMA’ which is enlisted as incurable as per DMR act however, Ayurvedic formulation LUKOSKIN has proved its worth and efficacy by providing benefit to over one lakh patients. Such immense potential of Ayurvedic science is now gaining the acceptance and slowly winning the world.

MILES TO GO….

The success of Ayurveda in rooting out the cause of disease justifies the time duration taken by the treatment still instead of this realization, Ayurveda has always been misinterpreted to be a slow acting therapy. The need of hour is dedicated and more extensive research in the concerned area to decipher more readily acting formulations from ancient text of Ayurveda which are yet, beyond our scope of understanding science. As any other parallel followed medical system, Ayurveda too hold the objective ‘TO HEAL’ and it is not Ayurvedic science which fails to validate its efficacy but it is us who stand short in apprehending the core of ‘AYURVEDA’. The research platform, Ayurvedic practitioners & Ayurvedic medicine manufacturers as a team we all need to work & try to mark our vision established that ‘AYURVEDA is not only a holistic healing approach but a workable science. And that will be a great source to instil the confidence about AYURVEDA among our people.

World Vitiligo Day- More Invention and Intervention needed

As of now, there is no FDA approved treatment modality for re-pigmenting the de-pigmented lesions.

 

The current bottleneck in Vitiligo is that the patho-mechanisms of the disorder are not well understood. Hence, the current treatments for Vitiligo provide only temporary and symptomatic relief.

Many life science companies are now focused on developing and commercializing novel therapeutics to address this unmet medical need.

Ahammune Biosciences Pvt Ltd is a Department of Industrial Policy & Promotion (DIPP) recognized startup company based in Pune, with current focus on this de-pigmenting disorder. “Vitiligo therapeutics has a projected market of $2.7 billion, with a CAGR of 8.8 per cent, making it an excellent business proposition. Ahammune is, to our knowledge, the first Vitiligo-centric drug discovery company. The emphasis at Ahammune is to first develop novel therapeutics in-house, and then establish collaborations or joint ventures, as necessary, to take the treatment options forward”, says Dr. Parul Ganju, Co-founder, Executive Director-Strategic planning and operations, Ahammune Biosciences Pvt Ltd.

At the same time innovative stem cell products are being developed by nurturing cutting edge research and clinical applications for fighting vitiligo. Mumbai-based Reliance Life Sciences has got government approval for conducting clinical trials with stem cells for vitiligo. The company has invested around Rs 1,000 crore in this business of stem cell therapies for many diseases with vitiligo being one of them.

As of now, there is no FDA approved treatment modality for re-pigmenting the de-pigmented lesions. But companies are spending on R&D for new and improved molecules that are not only effective but safe too.

Zydus Group deputy MD Sharvil P Patel emphasized on the step taken by the company in acquiring the lotion Melgain from Issar Pharma. “It is used for treatment of skin depigmentation and this product has strengthened our dermatological portfolio. With a strong presence in the hyperpigmentation, acne, haircare and anti-fungal segments, the expansion into the re-pigmentation segment gives Zydus an edge in the fast growing dermatology market which is currently growing at 14 per cent and valued at over Rs 6,000 crore”, he added.

PhotoMedex, a global skin health major from USA has invested about Rs. 300 crore to bring advanced VTRAC laser technology to treat Vitiligo and Psoriasis in India.

PhotoMedex India Private Limited, a subsidiary of global skin health company PhotoMedex Inc, has launched VTRAC certified clinics in Hyderabad. The company, in association with city-based Medium Healthcare Consulting (MHC), has set up five clinics in Hyderabad on a franchisee basis.

Pharmaceutical companies are also moving in the direction of promoting herbal products. The herbal drug, Lukoskin, developed by the scientists of the Defence Research and Development Organisation (DRDO) is now under commercial production by AIMIL Pharmaceuticals India Ltd.

Of the 1 per cent of world’s population suffering from vitiligo, 8.8 per cent of the cases are recorded in India. Vitiligo Day on June 25 is one such initiative, aimed to build global awareness about this disease and learn more facts.

BGR-34 article in Navbhatat times on 12 june 2017


BGR-34 in Top 20 List

1st time Ayurvedic Brand in Top 20


First time an Ayurvedic brand features in top 20 list of Best Launches in last 2 years among all allopathic MNC brands.

6367 Brands launched in Indian Pharma market in last 24 months… BGR-34 stands at 14th Rank among the Best Launches in Indian Pharma market for duration last 2 yrs.

Ayurvedic drug BGR-34 ‘Top 20’ brands of Best Launches in last 2 years amongst more than 6000 allopathic brands.

The government’s move to revive traditional medicines has started yielding results. In a major shot in the arms of Ayush Ministry, an ayurvedic drug developed by the Council of Scientific & Industrial Research (CSIR) has been adjudged as top 20 best medicines in the country. Notably, the Ayush Ministry was carved out from Health Ministry as a separate ministry to promote traditional medicines by PM Narendra Modi. “It’s for the time that an ayurvedic drug formulation has been included in the list of top 20 medicines which is mainly dominated by modern medicines.

The development establishes that patients are switching towards traditional healthcare system when it comes to treating diabetes,” an Ayush Ministry official said, adding that the BGR-34 medicine, which was developed by the CSIR, has been proving a better alternative to cure the non-communicable disease. The ayurvedic drug BGR-34 is at 14th position in the list which is dominated by the allopathic medicine of multinational companies such as Sanofi, Zydus, Lupin, etc. The ayurvedic formulation, which has been developed by CSIR –National Botanical Research Institute (NBRI) Lucknow is ranked at 33rd position in terms of MAT (moving annual total) value of the drug. The MAT value of a drug is declared after study its efficacy.

BGR-34 most cost-effective Ayurvedic medicine for diabetes

New Delhi, More than a year after its launch, BGR-34 remains the most cost-effective Ayurvedic medicine for diabetes, claims a top executive of AIMIL Pharmaceuticals, which manufactures and markets the medicine.

“BGR-34 is a natural DPP-4 (dipeptidyl peptidase 4) inhibitor with no side effects. It is the most cost-effective Ayurvedic medicine for diabetes available at Rs 5 per tablet for patients,” said K.K. Sharma, Managing Director, AIMIL.

DPP-4 inhibitors are a class of drugs used to lower blood sugar in adults with Type-2 diabetes.

The anti-diabetic herbal composition for Type-2 diabetes mellitus (NBRMAP-DB), which is sold under the trade name BGR-34, was developed by India’s Council of Scientific and Industrial Research (CSIR).

The knowhow was transferred to AIMIL Pharmaceuticals for the manufacture and sale of the medicine.

The medicine is known to contribute to the maintainence of normal blood glucose metabolism, restore quality of life and reduce the chances of long-term complications.

Clinical trials of the medicine conducted have found it to be effective for Type-2 diabetes mellitus, said AIMIL Pharmaceuticals, which launched NBRMAP-DB as “BGR-34” in the market in October 2015.

डायबिटीज की आयुर्वेदिक दवा दुनिया की Top 20 दवाओं में शामिल

सीएसआईआर और एनबीआरआई की ईजाद की गई मधुमेह यानी डायबिटीज पर कामयाब हुई दवा बीजीआर 34 ने दुनिया के टॉप 20 ब्रांड्स में अपनी जगह बना ली है. बीजीआर 34 अपनी गुणवत्ता और लोकप्रियता के मानकों पर 14वें पायदान पर रही. हैरानी की बात है कि बाकी सभी 19 दवाएं ऐलोपैथिक पद्धति से बनाई गई हैं. बीजीआर 34 इकलौती आयुर्वेदिक और भारतीय चिकित्सा पद्धति के आधार पर बनाई गई वैज्ञानिक दवा है.

ऑल इंडिया ओरिजिन केमिस्ट एंड डिस्ट्रीब्यूटर्स लिमिटेड यानी एआईओसीडी ने पिछले दो सालों में 6367 दवाओं का अध्ययन किया. अध्ययन के दौरान दवा के ब्रांड की बिक्री, मरीजों पर असर, साइड इफेक्ट सहित रैंकिग और मैट वैल्यू जैसे मानकों पर दवा को कसा जाता है. इसके बाद क्रमवार दर्जा दिया जाता है. इन सभी मानकों पर कसने के लिए सभी चिकित्सा पद्धतियों की टॉप दवाएं शामिल की गई थीं. पहली बार ऐसा हुआ है कि आयुर्वेदिक दवा शीर्ष 20 दवाओं के ब्रांड में शामिल हुई है.

इस उपलब्धि पर सीएसआईआर ने तो संतोष जताया ही है लेकिन सीएसआईआर के फार्मूले पर इस दवा का उत्पादन करने वाले एमिल फार्मा के चेयरमैन के के शर्मा ने कहा कि आधुनिक मानकों के मुताबिक आयुर्वेद की ये चमत्कारिक दवा तैयार करने का सेहरा सीएसआईआर के वैज्ञानिकों और उनकी अथक मेहनत को जाता है. यानी आयुर्वेद के फार्मूलों का अनुसंधान किया जाए तो और भी चमत्कार संभव हैं.

Click for more details

Information on this website is provided for informational purposes and is not meant to substitute for the advice provided by your own physician or other medical professionals. This website is meant for use by Indian residents only.